[1] BRUCE AC, LONGO DL.Harrison's Manual of Oncology(哈里森肿瘤学手册)[M]. Second edition. Beijing: Science Press, 2017. [2] National Health Committee of the People's Republic of China. About the printing of antineoplastic drugs clinical application management approach (trial)[S]. 2020. [3] The Ministry of Health of the People's Republic of China. Adverse drug reaction report and monitoring measures for the administration[S]. 2011. [4] ZHANG SG, ZHU JM.The treatment and prevention of adverse drug reactions(药品不良反应的预防与治疗)[M]. Beijing: Beijing Science and Technology Press, 2016. [5] YANG BF.Pharmacology(药理学) [M]. Ninth Edition. Beijing: People's Medical Publishing House, 2018. [6] ZENG WH.Clinical analysis and report of adverse drug reactions in elderly patients[J]. Contemporary Medicine(当代医学), 2017, 23(6): 23-24. [7] CHANG YF, NIU JQ.The analysis of the adverse drug reactions of the aged and the intervention of the rational use[J]. Smart Healthcare(智慧健康), 2020, 6(5): 151-152. [8] CHENG J, HAN Y, WANG L, et al.Analysis of 54 cases of adverse drug reactions induced by new antitumor drugs[J]. Chinese Journal of New Drugs(中国新药杂志), 2021, 30(3): 280-284. [9] WANG MM, MA JL, WANG XH, et, al. Analysis of 117 cases of adverse drug reactions induced by bevacizumab injection[J]. Evaluation and Analysis of Drug-use in Hospitals of China(中国医院用药评价与分析), 2020, 20(7): 872-875. [10] YU WT, WANG YX, JIANG G.Bibliometric analysis of bevacizumab-induced ADR[J]. China Pharmacy(中国药房), 2017, 28(2): 190-193. [11] LIU XZ, XU ZB, ZHANG XY.Meta-analysis of efficacy and security of bevacizumab combined with platinum in the treatment of advanced non-small-cell lung cancer[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2015, 32(11): 1382-1388. [12] FARIBA A, NCHARLOTTE OMT, ANTHONIUS DB, et a1. Efficacy and safety assessment of the addition of bevacizumab to adjuvant therapy agents in cancer patients: a systematic review and meta-analysis of randomized controlled trials[J]. Plos one, 2015, 10(9): e0136324. [13] ZHU D, CAO X, SONG YQ, et al.443 Cases of drug-induced adverse reactions in blood system[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 4(18): 356-360. [14] NING LJ, SU D, HUANG Y, et al.Analysis of serious adverse drug reactions of patients with malignant tumors in a grade-a class 3 hospital[J]. Pharmaceutical Services, 2020, 2(29): 40-42. [15] ZHANG F, ZHOU WQ.Management of infusion reactions to systemic anticancer therapy: ESMO clinical practice guidelines-an interpretation[J]. Journal of Nursing Science(护理学杂志), 2018, 9(33): 16-20. [16] MAGGI E,VUHAGGIO A, MATUCCI. Acute infusion reactions induced by monoclonal antibody therapy[J].Expert Rev Clin Immunol, 2011, 7(1): 55-63. [17] VUHAGGIO A, CASTELLS MC.Hypersensitivity reactions to biologic agents[J].Immunol Allergy Clin North Am, 2014, 34(3): 615-632. [18] GUAN M, ZHOU YP, SUN JL, et al.Adverse events of monoclonal antibodies used for cancer therapy[J]. Biomed Res Int, 2015, 2015: 428169. [19] VOGEL WH.Infusion reactions: diagnosis, assessment, and management[J].Clin J Oncol Nurs, 2010, 14(2):10-21. [20] TANG YX, FENG XM, ZHANG JX, et al.Therapeutic assessment of Bevacizumab injection into serous cavity in treatment of non -small cell lung cancer with malignant serous cavity effusion and analysis of predictive factors[J]. Journal of Navy Medicine(海军医学杂志), 2021, 3(42): 188-195. [21] MAO K.Investigation and analysis on adverse reactions induced by antineoplastic drugs in our hospital from 2015 to 2019[J]. China Medicine and Pharmacy(中国医药科学), 2021, 2(11): 165-167. [22] WANG NN, BAI Y, LIU H, et al.Characteristics of adverse reactions of antineoplastic drugs in 787 cases and the prognosis analysis[J]. Anti-tumor Pharmacy(肿瘤药学), 2019, 2(9): 143-148. |